Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “1 drop, 4 times a day (approximately every 4 hours while awake) for 5 days starting from Day 1.”In the company’s words, NCT06616922 on ClinicalTrials.gov
- Tested for
- Conjunctivitis, Bacterial
- Main trialPhase 2
- “This is a phase II, randomized, parallel-group, blinded-assessor, multicentre study to assess the non-inferiority of RD03/2016 eye drops vs. levofloxacin eye drops alone (1:1) in microbiological eradication in patients with a clinical diagnosis of bacterial conjunctivitis with moderate/severe signs.”In the company’s words, NCT06616922 on ClinicalTrials.gov
Other drugs for Conjunctivitis, Bacterial
- Fusidic Acid 1%Baxis Pharmaceuticals, Inc. · Phase 3
- SUM-191Senju USA, Inc. · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 14 Jun 2023 | Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026